Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
27 Setembro 2023 - 8:00AM
Matinas BioPharma (NYSE American: MTNB), a clinical-stage
biopharmaceutical company focused on redefining the intracellular
delivery of small molecules and small oligonucleotides with its
proprietary lipid nanocrystal (LNC) platform technology, announces
that MAT2203, its oral LNC formulation of amphotericin B (AMB),
will be featured in an oral company pipeline presentation at
IDWeek, being held October 11-15 at the Boston Convention and
Exhibition Center.
The presentation will be held as follows:
Title: |
MAT2203, a Novel Oral Delivery of Amphotericin B (AMB), in
Phase 3 Development for the Treatment of Invasive Fungal
Infections |
Session: |
New Antimicrobials in the Pipeline |
Date: |
Thursday, October 12, 2023 at 8:12 a.m. Eastern time |
Location: |
104 ABC |
Speaker: |
Theresa Matkovits, Ph.D., Chief Development Officer, Matinas |
"We are delighted to participate in this
important scientific conference and to highlight additional
clinical evidence from our Expanded Access Program supporting the
ability of MAT2203 to safely and effectively improve outcomes for
patients suffering from potentially deadly fungal infections," said
Dr. Matkovits. "The efficacy of AMB is well established, but use of
this potent fungicidal drug is typically administered selectively
and only to patients with severe disease because of its toxicity.
MAT2203 reduces the systemic toxicity associated with IV AMB by
delivering drug directly to targeted cells at the sites of
infection, supporting a favorable safety profile with the
additional benefit of oral administration.
"The compelling compassionate use data we will
be presenting at IDWeek as part of our pipeline overview support
our strategy to develop an ideal antifungal agent for the treatment
of a variety of invasive fungal infections while potentially having
a dramatic impact on the cost of treating these deadly diseases,"
she added.
About IDWeekIDWeek is the joint
annual meeting of the Infectious Diseases Society of America
(IDSA), Society for Healthcare Epidemiology of America (SHEA), the
HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases
Society (PIDS) and the Society of Infectious Diseases Pharmacists
(SIDP). IDWeek is a recognized forum for peer-reviewed
presentations of new research on scientific advances and
bench-to-bedside approaches in prevention, diagnosis, treatment and
epidemiology of infectious diseases. The 2023 event will be a
hybrid event with in-person and virtual attendance. For more
information, visit www.idweek.org.
About MAT2203Matinas BioPharma
is developing MAT2203 as a potential oral broad-spectrum treatment
for invasive deadly fungal infections. Although amphotericin B
(AMB) is a fungicidal agent, it is currently only available through
an intravenous route of administration, which is known to be
associated with a number of significant safety issues such as renal
toxicity and anemia due to very high circulating levels of drug.
MAT2203 has the potential to overcome the significant limitations
of the currently available AMB products by combining comparable
fungicidal activity with targeted oral delivery, resulting in a
lower risk of toxicity and potentially creating the ideal
antifungal agent for the treatment of invasive fungal infections.
MAT2203 is being positioned for a Phase 3 registrational study in
the treatment of invasive aspergillosis in patients with limited or
no treatment options.
About Matinas BioPharmaMatinas
BioPharma is a biopharmaceutical company focused on delivering
groundbreaking therapies using its proprietary lipid nanocrystal
(LNC) platform delivery technology.
Matinas’ lead LNC-based therapy is MAT2203, an
oral formulation of the broad-spectrum antifungal drug AMB, which
although highly potent, can be associated with significant
toxicity. Matinas’ LNC platform provides oral delivery of AMB
without the significant nephrotoxicity otherwise associated with
IV-delivered formulations. MAT2203 also allows for safe,
longer-term use outside the hospital setting, which could have a
substantial favorable pharmacoeconomic impact. MAT2203 was
successfully evaluated in the Phase 2 EnACT study in cryptococcal
meningitis, meeting its primary endpoint and achieving robust
survival. MAT2203 will be further evaluated as an oral step-down
monotherapy following treatment with IV AMB in a single pivotal
Phase 3 study for the treatment of aspergillosis in patients who
are unable to be treated with azoles for reasons related to
drug-drug interactions, resistance or other clinical reasons.
In addition to MAT2203, preclinical and clinical
data demonstrate that the LNC technology can provide safe and
effective intracellular delivery of both small molecules and
larger, more complex molecular cargos such as RNAi, antisense
oligonucleotides and vaccines. The combination of its unique
mechanism of action and flexible routes of administration
(including oral) holds potential for Matinas’ LNC technology to
become a preferred next-generation orally available intracellular
drug delivery platform. For more information, please visit
www.matinasbiopharma.com.
Forward-looking StatementsThis
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including
those relating to our business activities, our strategy and plans,
the future development of its product candidates, including
MAT2203, the Company’s ability to identify and pursue development,
licensing and partnership opportunities for its products, including
MAT2203, or platform delivery technology on favorable terms, if at
all, and the ability to obtain required regulatory approval and
other statements that are predictive in nature, that depend upon or
refer to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to continue as a going concern, our ability to obtain additional
capital to meet our liquidity needs on acceptable terms, or at all,
including the additional capital which will be necessary to
complete the clinical trials of our product candidates; our ability
to successfully complete research and further development and
commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor Contact
LHA Investor RelationsJody Cain
Jcain@lhai.com310-691-7100
Matinas Biopharma (AMEX:MTNB)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Matinas Biopharma (AMEX:MTNB)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024